Media Mice

No signal, no problem. A new digital platform is rethinking care beyond connectivity. GoodVision (Germany) has launched a digital platform designed to support eye care programs in underserved communities, no Wi-Fi required. Built on FieldKit, an open-source, offline-first data collection technology, the GoodVision App consolidates patient registration, vision screening, referral management and follow-up tracking into a single system.

CAKE Cataract Research & Evidence What does it take for a multifocal lens to become a go-to platform in real surgical practice? In this surgeon-to-surgeon discussion, Dr. William F. Wiley and Dr. Steven Dell share their real-world experience with the Bausch + Lomb enVista Envy™—focusing on two key areas of clinical decision-making: -The Dysphotopsia Conversation. How they counsel patients on nighttime visual phenomena and set realistic expectations in premium IOL cases. -The Future of Near Vision.

CAKE Glaucoma Tech and Pharma During canaloplasty, the viscoelastic doesn’t start in a ready state. It comes out balled up, tangled and sitting at high viscosity. Dr. Christine Funke and Prof. Arsham Sheybani explain what Shear Clear™ Technology actually changes. Under enough pressurization, the molecular structure temporarily shifts. The viscoelastic shears into a less viscous fluid, extending it far into the downstream outflow system.

Closing the gap between possibility and reality Cataract surgery is one of medicine’s fastest, most cost-effective fixes. So why is progress in Africa crawling? Emma Jolley unpacks the real bottlenecks: workforce shortages, patchy systems and policy gaps that keep a curable condition firmly out of reach. Emma Jolley (United Kingdom) doesn’t mince words when asked what drives her work in global eye health. “It’s a very strong sense of injustice for me,” she said. “Cataract surgery is there. It’s quick.

When retinal thickness improves but vision stands still, even promising therapies can find themselves on the cutting-room floor. Oculis, a Swiss-based biopharmaceutical company, has shelved plans for a U.S. Food and Drug Administration (FDA) filing of its investigational OCS-01 diabetic macular edema (DME) eye drop after two Phase III trials failed to meet their primary and key secondary vision endpoints.

CAKE Visionary Voices Glaucoma What does it really mean to be an interventionist in glaucoma? Five leading voices. One roundtable. A framework that’s changing how the field thinks about glaucoma management. Dr. Christine Funke, Dr. Morgan Micheletti, Dr. Manjool Shah, Dr. I. Paul Singh and Dr. Deborah Ristvedt go beyond IOP—challenging the assumptions behind how glaucoma is managed and what true intervention really looks like in practice. Follow us to catch the full conversation.

Two decades into a textbook academic career, one glaucoma surgeon steps off the well-lit stage—and into the surgical unknown—where dense cataracts, scarce resources and zero safety nets redefine what it means to operate. The result? Sharper skills, stripped-back dogma and a reminder that the real gold standard isn’t fancy tech—it’s impact. For nearly two decades, Prof.

CAKE Cataract Clinical Trials Tech and Pharma From selecting a phaco platform to an IOL patients actively recommend, this video from Bangalore, India brings two Rayner innovations into real-world surgical focus. Dr. Sri Ganesh, Dr. Supriya Sriganesh and Dr. Savio Pereira shared what defines performance in modern cataract surgery, starting with the core principles of phaco platform selection: fluidics, chamber stability and efficient cataract emulsification across all surgical levels.

How Rotterdam rewrote the rules of corneal surgery For decades, corneal surgeons replaced the whole to fix a part. In Rotterdam, that logic was flipped, ushering in precision-layer surgery with better outcomes, steeper learning curves and a global rollout still catching up. For a century, corneal transplantation meant removing the entire cornea and suturing in a replacement.

GA has long played hide-and-seek with visual function. This test may be getting better at seeking. Not everything worth measuring shows up on an eye chart. Patients with geographic atrophy (GA) often experience mounting difficulty with reading and facial recognition even while maintaining relatively good visual acuity—a gap that standard testing routinely misses.